|Affymetrix Reports Fourth Quarter and Fiscal Year 2013 Results|
|SANTA CLARA, Calif.--(BUSINESS WIRE)--Feb. 5, 2014--
Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results
for the three and twelve months ended December 31, 2013.
Results for the three months ended December 31, 2013:
Total revenue was $92.6 million, which included revenue from
eBioscience of $20.5 million.
Product revenue was $82.1 million, as compared to product revenue for
the four... ||02/05/14|
|Affymetrix Receives FDA Clearance of First-of-its-kind Postnatal Test for Developmental Delays and Intellectual Disabilities in Children|
|CytoScan® Dx Assay represents a technology
leap over traditional postnatal genetic tests and significantly improves
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 21, 2014--
Inc. (NASDAQ: AFFX) today announced that it has received 510(k) clearance
from the U.S. Food and Drug Administration (FDA) to market its
CytoScan® Dx Assay. This assay is intended for the postnatal
detection of DNA copy number variants ... ||01/21/14|
|University of Bristol Collaborates with Affymetrix on Genotyping Arrays for Guaranteed Sustainability of Wheat Production|
|SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 13, 2014--
Inc. (NASDAQ: AFFX) and University of Bristol, Bristol, UK,
announced today that they have collaboratively designed a wheat
genotyping array and analyzed data from experiments as part of an effort
to understand wheat genetics and breeding with a goal of ensuring
guaranteed sustainable production.
Axiom® Wheat Genotyping Array (Axiom Wheat Array), consisting
of 817,000... ||01/13/14|
|— Affymetrix Announces Preliminary Fourth Quarter 2013 Revenue of Approximately $91 Million —|
|SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 7, 2014-- Affymetrix, Inc., (NASDAQ: AFFX) today announced that based on preliminary, unaudited financial data, the Company expects total revenue for the fourth quarter of 2013 will be approximately $91 million, including a one-time licensing payment of $5.3 million from a diagnostic partner. For fiscal 2013, the Company expects total revenue of approximately $329 million.
"In 2013 we executed effectively against our three phase strategic plan and we ... ||01/07/14|